---
title: "Virax Biolabs climbs 7% during trading on Fosun Diagnostics supply deal"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292920225.md"
description: "Virax Biolabs rises 7% to $3.68 on ImmuneSelect supply agreement with Fosun Diagnostics covering six Southeast Asian markets."
datetime: "2026-07-16T14:21:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292920225.md)
  - [en](https://longbridge.com/en/news/292920225.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292920225.md)
generator: "portal-rs"
---

# Virax Biolabs climbs 7% during trading on Fosun Diagnostics supply deal

Virax Biolabs(VRAX.US) 盘中涨**6.67%**，现报**3.68**美元。

消息面上，公司与复星诊断（Fosun Diagnostics）签署 ImmuneSelect 产品商业供应协议，覆盖东南亚六个市场。该协议聚焦近期供应与评估，初期针对泰国结核病研究领域。Virax 计划借助复星网络实现区域扩张，将需求转化为收入。

### Related Stocks

- [VRAX.US](https://longbridge.com/en/quote/VRAX.US.md)

## Related News & Research

- [Virax Biolabs announces extraordinary shareholder meeting](https://longbridge.com/en/news/294507736.md)
- [Virax Mulls Bringing UK Biotech Startup’s Immune Profiling Platform to China, Chair Says](https://longbridge.com/en/news/285902519.md)
- [Nanjing Leads Biolabs says NMPA accepts NDA for LBL-024 in advanced EP-NEC](https://longbridge.com/en/news/296590195.md)
- [Virax Biolabs signs Fosun Diagnostics supply deal for ImmuneSelect in six Southeast Asian markets](https://longbridge.com/en/news/292898428.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**